Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747]

Rachael A Evans; Sabada Dube; Yi Lu; Mark Yates; Sofie Arnetorp; Eleanor Barnes; Samira Bell; Lucy Carty; Kathryn Evans; Sophie Graham; Nahila Justo; Paul Moss; Sudhir Venkatesan; Renata Yokota; Catia Ferreira; Richard McNulty; Sylvia Taylor; Jennifer K Quint

doi:10.1016/j.lanepe.2024.101008

Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health - Europe 35 (2023) 100747]

Lancet Reg Health Eur. 2024 Jul 25:44:101008. doi: 10.1016/j.lanepe.2024.101008. eCollection 2024 Sep.

Authors

Rachael A Evans¹, Sabada Dube², Yi Lu³, Mark Yates⁴, Sofie Arnetorp⁵, Eleanor Barnes⁶, Samira Bell⁷, Lucy Carty⁸, Kathryn Evans⁹, Sophie Graham³, Nahila Justo¹⁰, Paul Moss^{11

12}, Sudhir Venkatesan¹³, Renata Yokota¹⁴, Catia Ferreira¹⁵, Richard McNulty¹⁶, Sylvia Taylor¹⁷, Jennifer K Quint¹⁸

Affiliations

¹ Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom.
² AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom.
³ Evidera, The Ark, 201 Talgarth Road, London, W6 8BJ, United Kingdom.
⁴ Data Analytics - Real World Evidence, Evidera, London, United Kingdom.
⁵ Vaccines and Immune Therapies, Global Market Access and Pricing, AstraZeneca R&D, 431 83, Mölndal, Sweden.
⁶ Nuffield Department of Medicine, University of Oxford, OUH Hospital NHS Trust, Oxford, United Kingdom.
⁷ Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, Scotland, United Kingdom.
⁸ Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
⁹ Evidera, Waltham, MA 02451, United States.
¹⁰ Integrated Solutions - Real World Evidence, Evidera, Stockholm, Sweden.
¹¹ Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
¹² University Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom.
¹³ Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
¹⁴ P95, Leuven, Belgium.
¹⁵ AstraZeneca LP, 1800 Concord Pike, Wilmington, DE, 19850-5437, USA.
¹⁶ Medical Affairs, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom.
¹⁷ Medical Evidence, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom.
¹⁸ National Heart & Lung Institute, Imperial College London, United Kingdom.

Abstract

[This corrects the article DOI: 10.1016/j.lanepe.2023.100747.].

Publication types

Published Erratum